LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis
Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study
Elazığ Mental Health and Diseases Hospital
120 participants
Sep 1, 2025
OBSERVATIONAL
Conditions
Summary
This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.
Eligibility
Inclusion Criteria17
- For Methamphetamine Use Disorder (MUD) Group:
- Diagnosis of MUD according to DSM-5-TR
- Medication-free for at least one month prior to admission
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Methamphetamine Use Disorder (MUD) Group:
- Diagnosis of MP according to DSM-5-TR
- Medication-free for at least one month prior to admission
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Methamphetamine-Induced Psychotic Disorder (MP) Group:
- No psychiatric diagnosis
- No systemic or immunological illness
- Medication-free for at least one month
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Healthy Control Group:
Exclusion Criteria32
- • Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than MUD
- Alcohol use disorder
- For Methamphetamine-Induced Psychotic Disorder (MP) Group:
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than MP
- Alcohol use disorder
- For Healthy Control Group:
- • Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than schizophrenia
- Alcohol/drug/substance use
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07450027